Kamaruzzaman Nor F, Chong Stacy Q Y, Edmondson-Brown Kamina M, Ntow-Boahene Winnie, Bardiau Marjorie, Good Liam
Department of Pathology and Pathogen Biology, Royal Veterinary CollegeLondon, United Kingdom.
Centre for Expertise in the Treatment and Management of Water (CEBEDEAU)Liège, Belgium.
Front Microbiol. 2017 Aug 11;8:1518. doi: 10.3389/fmicb.2017.01518. eCollection 2017.
infection is a common cause of mastitis, reducing milk yield, affecting animal welfare and causing huge economic losses within the dairy industry. In addition to the problem of acquired drug resistance, bacterial invasion into udder cells and the formation of surface biofilms are believed to reduce antibiotic efficacy, leading to treatment failure. Here, we investigated the antimicrobial activities of enrofloxacin, an antibiotic that is commonly used in mastitis therapy and polyhexamethylene biguanide (PHMB), an antimicrobial polymer. The antimicrobial activities were tested against intracellular in infected Mac-T cells (host cells). Also, fluorescein-tagged PHMB was used to study PHMB uptake and localization with within the infected Mac-T cells. Anti-biofilm activities were tested by treating biofilms and measuring effects on biofilm mass . Enrofloxacin and PHMB at 15 mg/L killed between 42 to 92 and 99.9% of intracellular , respectively. PHMB-FITC entered and colocalized with the intracellular , suggesting direct interaction of the drug with the bacteria inside the host cells. Enrofloxacin and PHMB at 15 mg/L reduced between 10 to 27% and 28 to 37% of biofilms' mass, respectively. The half-maximal inhibitory concentrations (IC) obtained from a cytotoxicity assay were 345 ± 91 and 21 ± 2 mg/L for enrofloxacin and PHMB, respectively; therefore, both compounds were tolerated by the host cells at high concentrations. These findings suggest that both antimicrobials are effective against intracellular and can disrupt biofilm structures, with PHMB being more potent against intracellular , highlighting the potential application of PHMB in mastitis therapy.
感染是乳腺炎的常见病因,会降低产奶量,影响动物福利,并给乳制品行业造成巨大经济损失。除了获得性耐药问题外,细菌侵入乳腺细胞并形成表面生物膜被认为会降低抗生素疗效,导致治疗失败。在此,我们研究了恩诺沙星(一种常用于乳腺炎治疗的抗生素)和聚六亚甲基双胍(PHMB,一种抗菌聚合物)的抗菌活性。针对感染的Mac-T细胞(宿主细胞)内的细菌测试了抗菌活性。此外,使用荧光素标记的PHMB来研究PHMB在感染的Mac-T细胞内的摄取和定位。通过处理生物膜并测量对生物膜质量的影响来测试抗生物膜活性。15 mg/L的恩诺沙星和PHMB分别杀死了42%至92%和99.9%的细胞内细菌。PHMB-异硫氰酸荧光素进入细胞内并与细菌共定位,表明该药物与宿主细胞内的细菌直接相互作用。15 mg/L的恩诺沙星和PHMB分别使生物膜质量减少了10%至27%和28%至37%。从细胞毒性试验获得的半数最大抑制浓度(IC),恩诺沙星和PHMB分别为345±91和21±2 mg/L;因此,两种化合物在高浓度下均能被宿主细胞耐受。这些发现表明,两种抗菌剂对细胞内细菌均有效,且能破坏生物膜结构,其中PHMB对细胞内细菌更有效,突出了PHMB在乳腺炎治疗中的潜在应用。